Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)
Public ClinicalTrials.gov record NCT04480424. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit
Study identification
- NCT ID
- NCT04480424
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Interventions
- GAMUNEX-C Biological
- Standard Medical Treatment Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 16, 2020
- Primary completion
- Aug 24, 2021
- Completion
- Oct 24, 2021
- Last update posted
- Oct 6, 2022
2020 – 2021
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Chandler Regional Medical Center | Chandler | Arizona | 85224 | — |
| Southern California Research Center | Coronado | California | 92118 | — |
| University of Illinois at Chicago | Chicago | Illinois | 60612 | — |
| Via Christi Research | Wichita | Kansas | 67214 | — |
| University of Louisville | Louisville | Kentucky | 40202 | — |
| Louisiana State University Health Sciences Center | Shreveport | Louisiana | 71103 | — |
| McLaren Flint | Flint | Michigan | 48532 | — |
| McLaren Health Care-Macomb | Mount Clemens | Michigan | 48043 | — |
| McLaren Health Care Oakland | Pontiac | Michigan | 48342 | — |
| CHI Health | Omaha | Nebraska | 68124 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Wake Forest Baptist Medical Center | Winston-Salem | North Carolina | 27517 | — |
| Summa Health | Akron | Ohio | 44304 | — |
| Temple University Hospital | Philadelphia | Pennsylvania | 19140 | — |
| Allegheny Health Network Research Institute | Pittsburgh | Pennsylvania | 15212 | — |
| CHRISTUS Health | Tyler | Texas | 75701 | — |
| MultiCare Deaconess Hospital | Spokane | Washington | 99204 | — |
| MultiCare Tacoma General Hospital | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04480424, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2022 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04480424 live on ClinicalTrials.gov.